Soleno Therapeutics had its Relative Strength (RS) Rating upgraded from 78 to 83 Monday.
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an 80 or higher RS Rating as they launch their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Soleno Therapeutics is working on a consolidation with a 60.92 entry. See if it can break out in heavy volume. Keep in mind that it's a later-stage consolidation, and those are riskier than earlier-stage patterns.
Soleno Therapeutics showed 0% EPS growth in its most recent report. Revenue rose 0%.
The company holds the No. 53 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
